Absence of significant adverse events following thalidomide administration in bitches diagnosed with mammary gland carcinomas

The aim of the study was to evaluate the incidence of adverse events (AEs) in female dogs diagnosed with advanced clinical stage mammary gland neoplasms following treatment with thalidomide. A prospective analysis of 29 female dogs treated with a high dose (HD) of 20 mg/kg/day of thalidomide for thr...

Full description

Saved in:
Bibliographic Details
Published in:Veterinary record 2016-11, Vol.179 (20), p.514-514
Main Authors: de Campos, C. B., Lavalle, G. E., Fialho Ligório, S, Camargo Nunes, F., Carneiro, R. A., Amorim, R. L., Cassali, G. D.
Format: Article
Language:English
Subjects:
Adverse events
Anesthesia
Animals
Cancer therapies
Carcinoma - drug therapy
Carcinoma - pathology
Carcinoma - veterinary
Chemotherapy
Disease
Dog Diseases - drug therapy
Dog Diseases - pathology
Dogs
Dose-Response Relationship, Drug
Drug dosages
Female
Mammary gland
Mammary Neoplasms, Animal - drug therapy
Mammary Neoplasms, Animal - pathology
Metastasis
Neoplasm Staging
Oncology
Prospective Studies
Thalidomide
Thalidomide - administration & dosage
Thalidomide - adverse effects
Treatment Outcome
Tumors
Veterinary medicine
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The aim of the study was to evaluate the incidence of adverse events (AEs) in female dogs diagnosed with advanced clinical stage mammary gland neoplasms following treatment with thalidomide. A prospective analysis of 29 female dogs treated with a high dose (HD) of 20 mg/kg/day of thalidomide for three months followed by a low dose (LD) of 10 mg/kg/day of thalidomide for three months was performed. All patients underwent physical examination, complete blood count, serum biochemistry profile, thoracic radiographs, and abdominal ultrasound analysis before the treatment and after the HD and LD. Clinical AEs were absent in 16/29 (55.17 per cent) patients following HD. An initial 3–5 day period of somnolence was described in 4/29 (13.79 per cent), prolonged somnolence in 5/29 (17.24 per cent), a short period of somnolence lasting only a few hours in 3/29 (10.34 per cent), and difficulty to rouse was described in 5/29 (17.24 per cent) cases. Two patients (6.89 per cent) presented with prolonged somnolence that interfered with activities of daily living, resulting in anticipation of the dose reduction to the proposed LD after 15 days of the HD treatment. Following dose reduction, AE improvement was observed in all patients. Albeit remaining within the reference ranges, erythrocytes, haematocrit, total leucocyte count, neutrophils, lymphocytes, monocytes and γ-glutamyltranspeptidase showed significant alteration associated to thalidomide treatment.
ISSN:0042-4900
2042-7670
DOI:10.1136/vr.103764